OBR Daily Commentary

forumImage

Survey Shows Less Than Half of Men With Prostate Cancer Are Referred to an Oncologist

(Yahoo! News) June 12, 2014 - A new prostate cancer survey revealed that only 41 percent of men with prostate cancer were referred to an oncologist at some point during their prostate cancer journey.

Read Article arrow

Robert A. Figlin, MD., FACP (Posted: June 13, 2014)

quotesProstate Cancer treatment is evolving. Fewer patients are requiring surgery as we better understand how to manage patients with lower Gleason scores and Active Surveillance is becoming an increasingly important consideration. Recent reports at ASCO 2014 demonstrated that chemotherapy when combined with hormonal therapy extends survival. The impact on the practice of urology and the integration of the medical oncologist into a patient's care is more important now than ever. It is not an understatement to say that the treatment of prostate cancer should be multidisciplinary and that urologists, medical oncologist, radiation oncologists should be participating in their management and prostate cancer patients should be requesting this approach to understand all of their options.quotes

Add Comment 2 Comment
forumImage

Panel Urges Higher Bar for Cancer Trials

(MedPage Today) Mar 18, 2014 - Oncology clinical trials should be designed so that the primary endpoint of overall survival benefit is a more meaningful one, and patients should expect no less, according to an oncology research panel.

Read Article arrow

Robert A. Figlin, MD., FACP (Posted: March 18, 2014)

quotesThe endpoints for a clinical trial as pointed out by this oncology research panel should have meaningful clinical benefit on behalf of the patient. Too often clinical trials are developed for endpoints that have marginal clinical benefit and then the agents used are left to a marketing team to influence physician behavior. This panel is to be applauded for developing a set of guidelines that will set the bar for new therapies. In this era of cost sensitivity, guiding principles such as these are necessary to balance risk and benefit while aligning "value" as an endpoint in delivering therapies.quotes

Add Comment 1 Comment
forumImage

Targeted Tx Fails 2 Tests in Metastatic Renal Cancer

(MedPage Today/The Gupta Guide) Dec 4, 2013 - A mammalian target of rapamycin (mTOR) inhibitor failed to improve outcomes in metastatic renal cell carcinoma (RCC) as compared with other therapeutic options, according to two randomized trials.

Read Article arrow

Robert A. Figlin, MD., FACP (Posted: December 05, 2013)

quotesThe reports today of the lack of benefit from two randomized trials in renal cancer highlight the need for additional approaches in this disease. We still have but two targets in RCCa that have led to multiple FDA approvals. Those targets are the VEGF and the mTOR pathways. Despite significant advances these trials demonstrate that the benefits from additional trials targeting these pathways either alone or in combinations are not demonstrating advantages for patients. It is time to move on. We are doing so with recent efforts targeting the cMET pathway as well as agents in pivotal trials targeting checkpoint inhibition. Continuing to understand the biology of this disease while developing novel therapeutics should remain our focus.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...